Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Pantelia Roussou"'
Autor:
Paola Guglielmelli, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Minghui Duan, Haitao Meng, Ling Pan, Guangsheng He, Srdan Verstovsek, Françoise Boyer, Fiorenza Barraco, Dietger Niederwieser, Ester Pungolino, Anna Marina Liberati, Claire Harrison, Pantelia Roussou, Monika Wroclawska, Divyadeep Karumanchi, Karen Sinclair, Peter A.W. te Boekhorst, Heinz Gisslinger
Publikováno v:
Therapeutic Advances in Hematology, Vol 13 (2022)
Background: Thrombocytopenia is a common feature of myelofibrosis (MF), a myeloproliferative neoplasm driven by dysregulated JAK/STAT signaling; however, pivotal trials assessing the efficacy of ruxolitinib (a JAK1/2 inhibitor) excluded MF patients w
Externí odkaz:
https://doaj.org/article/d9a8c4a6c15d4398ace68f263124dc8d
Autor:
Claire Harrison, Florian H. Heidel, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Amjad Hayat, Francesco Passamonti, Eibhlin Conneally, Thomas Kindler, Bruno Martino, Daniel B. Lipka, Tommaso Stefanelli, Pantelia Roussou, Davide Germano, Jacqueline Ewan, Vincent Ribrag
Publikováno v:
HemaSphere, Vol 6, Iss 8, p e757 (2022)
Externí odkaz:
https://doaj.org/article/e4ad9ac6fbc047909aa7e4c5b130001e
Autor:
Franco Locatelli, Hyoung Jin Kang, Bénédicte Bruno, Virginie Gandemer, Fanny Rialland, Maura Faraci, Yoshiyuki Takahashi, Katsuyoshi Koh, Henrique Bittencourt, Grace Cleary, Christine Rosko, Pantelia Roussou, Annie St. Pierre, Anirudh Prahallad, Cristina Díaz-de-Heredia
Publikováno v:
Blood. 140:1376-1378
Autor:
Peter A. W. te Boekhorst, Kevin Majidi, Françoise Boyer-Perrard, Fiorenza Barraco, Heinz Gisslinger, Monika Wroclawska, Guangsheng He, Anna Marina Liberati, Minghui Duan, Ling Pan, Pantelia Roussou, Jean-Jacques Kiladjian, Dietger Niederwieser, Srdan Verstovsek, Alessandro M. Vannucchi, Paola Guglielmelli, Haitao Meng, Claire N. Harrison
Publikováno v:
Blood. 136:4-5
BACKGROUND RUX, a potent oral JAK1/JAK2 inhibitor, has shown superiority over standard therapies in MF. RUX was approved for the treatment of MF on the basis of the phase 3 COMFORT trials, in which RUX led to sustained improvements in splenomegaly an
Autor:
Pantelia Roussou, Hiroshige Yoshioka, Paola Aimone, Martin Reck, Emmanuelle di Tomaso, Jean-Charles Soria, Wu Chou Su, Francesco Grossi, Johan Vansteenkiste, Filippo de Braud, Sumitra Thongprasert, Cesare Gridelli, Jhanelle E. Gray, Tommaso De Pas, Grace K. Dy, Gena Vidam, Enriqueta Felip, Ying A. Wang, Jean-Luc Canon
Publikováno v:
Journal of Thoracic Oncology. 10(9):1319-1327
Introduction The phosphatidylinositol 3-kinase (PI3K) pathway promotes tumor growth and treatment resistance in non-small cell lung cancer (NSCLC). The aim of the open-label, two-stage, Phase II study BASALT-1 (NCT01820325) was to investigate the pan
Autor:
Mikhail Shtivelband, JT Beck, Pantelia Roussou, Carlos Becerra, Vincent Duval, Pierre Fumoleau, E. di Tomaso, Patrick Urban, Ander Urruticoechea, M. Campone, M Gil-Martin, Nicolas Isambert
Publikováno v:
Cancer Research. 72:P6-11
Background: The PI3K/AKT/mTOR pathway is frequently altered in breast cancer (BC). Alterations in PIK3CA or inactivation of PTEN are observed in 10–40% and in up to 50% of breast tumors, respectively. The PI3K/AKT/mTOR pathway can be further activa
Autor:
J. Thaddeus Beck, Pantelia Roussou, Suzette Delaloge, Petr Krivorotko, Patrick Urban, Manuel Ruiz Borrego, Arlene Chan, Roberto Hegg, Norberto Batista López, Qamar J. Khan, Joyce O'Shaughnessy, Alexey Manikhas, Mario Campone, Mikhail Shtivelband, Cristian Massacesi, Miguel Martín, Emmanuelle di Tomaso, Manuel Ramos Vasquez, Luc Dirix
Publikováno v:
Molecular Cancer Therapeutics. 14:A166-A166
Introduction: Phosphatidylinositol 3-kinase (PI3K) pathway activation in breast cancer (BC) is associated with tumor growth and resistance to anticancer therapies, including paclitaxel (PAC). Combined treatment with the pan-Class I PI3K inhibitor bup
Autor:
Johan Vansteenkiste, Sumitra Thongprasert, J-L Canon, Marlene Thomas, J. De Greve, J-C. Soria, Francesco Grossi, Martin Reck, W. Su, T. De Pas, C. Gridelli, Paola Aimone, Pantelia Roussou, Hiroshige Yoshioka, Jhanelle E. Gray, Grace K. Dy, G. Atalla-Vidam, Enriqueta Felip
Publikováno v:
Annals of Oncology. 25:iv458
Aim: In vitro, NSCLC cell lines with PIK3CA mutations have shown increased sensitivity to the oral pan-PI3K inhibitor buparlisib (BKM120). BASALT-1 is an open-label, two-stage, Phase II study to assess the safety and efficacy of buparlisib in patient